Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’
BIO CEO Panel Discusses Pros And Cons
Executive Summary
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
You may also be interested in...
UK Firms Big And Small Benefit From Biotech Bubble
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.
Pipeline Watch: Phase III Starts In Psoriasis, Menopause, And COVID-19 Prevention
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.